When was Orange Grove Bio LLC founded?

Orange Grove Bio LLC was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Orange Grove Bio LLC located?

Orange Grove Bio LLC is headquartered in New York City, United States.

Who is the current CEO of Orange Grove Bio LLC?

Marc Spencer Appel of Orange Grove Bio LLC.

How many employees does Orange Grove Bio LLC have?

As of Mar 31, 2026, the latest employee count at Orange Grove Bio LLC is 24.

Is Orange Grove Bio LLC a funded company?

Orange Grove Bio LLC is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Aug 25, 2022.

When was the latest funding round of Orange Grove Bio LLC?

Orange Grove Bio LLC's latest funding was a $***** Series B round on Aug 25, 2022, with participation from 0 investor.

Where does Orange Grove Bio LLC rank among its competitors?

Orange Grove Bio LLC ranks 5th amongst 49 active competitors, of which 4 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Oncodesign, which secured $6.92M in Mar, 2026.

Who are the top competitors of Orange Grove Bio LLC?

Orange Grove Bio LLC's top competitors include Crown Bioscience, Oncodesign and TD2. Among them, Oncodesign secured the most recent funding round in March, 2026.

Orange Grove Bio LLC - 2026 Company Profile, Team, Funding & Competitors

Orange Grove Bio LLC is a series B company based in New York City (United States), founded in 2019 by Lutz B Giebel and Marc Spencer Appel. It operates as a Provider of preclinical development services. Orange Grove Bio LLC has raised $16.6M in funding. The company has 49 active competitors, including 4 funded and 8 that have exited. Its top competitors include companies like Crown Bioscience, Oncodesign and TD2.

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Series B

Total Funding

$16.6M in 1 round

Latest Funding Round

Series B, Aug 25, 2022, $*****

Investors

AlleyCorp & 1 more

Ranked

5^th among 49 active competitors

Employee Count

24 as on Mar 31, 2026

Similar Companies

Crown Bioscience & 57 more

View Orange Grove Bio LLC's full profile

Orange Grove Bio LLC has raised a total funding of $16.6M over 1 round. Orange Grove Bio LLC has 2 institutional investors.

Here is the list of recent funding rounds of Orange Grove Bio LLC:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2022	9304218	Series B	1892735	3539660	3155217	6188681

Access funding benchmarks and valuations. Sign up today!

View details of Orange Grove Bio LLC's funding rounds and investors

The founders of Orange Grove Bio LLC are Lutz B Giebel and Marc Spencer Appel.

Here are the details of Orange Grove Bio LLC's key team members:

Lutz B Giebel: Co-Founder of Orange Grove Bio LLC.
Contact Info: 1 email address
Marc Spencer Appel: Former Founder & CEO of Orange Grove Bio LLC.

View details of Orange Grove Bio LLC's Founder profiles and Board Members

Orange Grove Bio LLC's employee count trend

Orange Grove Bio LLC has 24 employees as of Mar 26. Here is Orange Grove Bio LLC's employee count trend over the years:

Employee count trend for Orange Grove Bio LLC

Uncover Orange Grove Bio LLC's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orange Grove Bio LLC include Crown Bioscience, Oncodesign and TD2. Here is the list of Top 10 competitors of Orange Grove Bio LLC, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Crown Bioscience 2006, Santa Clara (United States), Acquired	Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases)	$85.9M	The CID Group, Orbimed & 16 others	72/100
2nd	Oncodesign 1995, Dijon (France), Acquired	Provider of preclinical assessment services for anticancer therapies	$4.71M	Banque de Vizille, Avenir Entreprises & 3 others	60/100
3rd	TD2 2003, Phoenix (United States), Acquired	Oncology CRO accelerating cancer drug development with integrated preclinical and clinical services	-	-	41/100
4th	LumaBridge 2013, San Antonio (United States), Acquired	Provider of oncology clinical research, regulatory affairs, and data management services	-	Summit Partners	40/100
5th	Orange Grove Bio LLC 2019, New York City (United States), Series B	Provider of preclinical development services	$16.6M	AlleyCorp, Catalytic Impact Foundation	39/100
6th	Lytica Therapeutics 2019, Cambridge (United States), Series A	Developer of therapeutic drugs	$5.82M	CARB-X	38/100
7th	Orakl Oncology 2023, Villejuif (France), Seed	Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.	$14.7M	Speedinvest, Singular & 3 others	36/100
8th	Exigent Research 2022, Stockton (United States), Unfunded	Provider of clinical cancer research access and care through partnerships with independent oncology clinics.	-	-	32/100
9th	Misvik Biology 2014, Turku (Finland), Funding Raised	Provider of precision oncology contract research and toxicology research services	-	Europa	32/100
10th	ONCOtracker 2014, West Hollywood (United States), Seed	Developer of immune assays for the diagnosis of cancer	$1.3M	-	31/100